J Korean Diabetes > Volume 15(3); 2014 > Article
The Journal of Korean Diabetes 2014;15(3):146-150.
DOI: https://doi.org/10.4093/jkd.2014.15.3.146    Published online September 30, 2014.
SGLT2 억제제의 혈당 강하 효과
김혜진
Glucose Lowering Effect of SGLT2 Inhibitors: A Review of Clinical Studies.
Hae Jin Kim
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea. jinkim@ajou.ac.kr
Abstract
There are numerous glucose lowering agents in clinical use for type 2 diabetic patients, yet most do not achieve glycemic targets. Recently, inhibitors of the sodium glucose cotransporter 2 (SGLT2) have been developed, which show great potential of being a novel therapeutic option to treat type 2 diabetes. Many researches have turned their attention to the kidney as a target because renal glucose reabsorption is increased in type 2 DM. SGLT2 is a protein transporter that mediates glucose reabsorption from glomerular filtrates. In an insulin-independent manner, inhibition of SGLT2 increases urinary glucose excretion and decreases plasma glucose levels. To date, there are a few SGLT2 inhibiting agents being clinically studied both as a monotherapy and in combination with other antidiabetic agents. This review will focus on the efficacy of SGLT2 inhibitors based on clinical studies.
Key Words: Hypoglycemic agents, Sodium glucose cotransporter 2, Type 2 diabetes mellitus
TOOLS
METRICS Graph View
  • 0 Crossref
  •  0 Scopus
  • 808 View
  • 3 Download
Related articles

The Non-glycemic Effects of SGLT2 Inhibitor.2014 September;15(3)



Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2022 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer